Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 9/20 | 0.68 |
| ▸ | JAK3 known ✓ | P52333 | 5/20 | 0.51 |
| ▸ | BTK known ✓ | Q06187 | 1/20 | 0.49 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.79 |
| ▸ | KDR | P35968 | 3/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.79 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL16514197 | 1.00 | FGFR1 (0.79) | FGFR1KDRFGFR2EGFRJAK3 | |
| Maleic Acid SCHEMBL16514196 | 1.00 | FGFR1 (0.79) | FGFR1KDRFGFR2EGFRJAK3 | |
| SCHEMBL16514365 | 0.96 | FGFR1 (0.84) | FGFR1KDRFGFR2EGFRJAK3 | |
| SCHEMBL29847633 | 0.96 | FGFR1 (0.84) | FGFR1KDRFGFR2EGFRJAK3 | |
| Rx-518 SCHEMBL16514840 | 0.92 | FGFR2 (0.93) | FGFR1KDRFGFR2EGFRJAK3 | |
| Rx-518 SCHEMBL16514843 | 0.92 | FGFR2 (0.93) | FGFR1KDRFGFR2EGFRJAK3 | |
| SCHEMBL16514084 | 0.89 | FGFR1 (0.72) | FGFR1KDRFGFR2EGFRJAK3 | |
| SCHEMBL16514255 | 0.89 | FGFR1 (0.72) | FGFR1KDRFGFR2EGFRJAK3 | |
| SCHEMBL29848110 | 0.89 | FGFR1 (0.72) | FGFR1KDRFGFR2EGFRJAK3 | |
| Rx-518 SCHEMBL16514522 | 0.88 | FGFR2 (1.00) | FGFR1KDRFGFR2EGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | EGFR 518/4885JAK3 335/4885BTK 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.